Federal Investigation into UnitedHealth’s Medicare Advantage Program Seen as Lengthy and Complex
The ongoing federal investigation into UnitedHealth Group’s Medicare Advantage program is shaping up to be one of the most significant and protracted probes into Medicare fraud in recent history. UnitedHealth, the nation’s largest provider of Medicare Advantage benefits, is cooperating with both criminal and civil investigations launched by the Department of Justice (DOJ). However, experts suggest that the case is unlikely to be resolved quickly due to its complexity and the high stakes involved.
Medicare Advantage: A Growing Focus of Scrutiny
Medicare Advantage is a privatized alternative to traditional Medicare, managed by private insurers like UnitedHealthcare. Over the past 15 years, this program has grown substantially, now covering more beneficiaries than traditional Medicare. This expansion has drawn increased attention from regulators and lawmakers concerned about potential fraud and abuse within the system.
Central to the investigations are allegations that Medicare Advantage insurers, including UnitedHealthcare, have manipulated diagnosis codes to exaggerate patients’ health conditions. This practice, known as “upcoding,” artificially inflates the risk scores used by Medicare to determine payments, resulting in higher reimbursement rates. A 2024 report from the U.S. Department of Health and Human Services’ inspector general identified UnitedHealth as a notable user of questionable diagnosis data to boost payments, although the company has disputed these findings.
Civil Settlements Signal Broader Industry Challenges
The scrutiny of Medicare Advantage programs is not limited to UnitedHealth. Several other major insurers and healthcare providers have reached multi-million dollar settlements over similar allegations of false or inaccurate diagnosis coding aimed at increasing Medicare payments.
Notable recent cases include:
-
Cigna’s $170 million settlement in 2023 to resolve claims of submitting inaccurate diagnosis codes, accompanied by a five-year corporate integrity agreement requiring rigorous audits.
-
Seoul Medical Group’s $58.7 million settlement for alleged false diagnosis submissions.
-
Independent Health’s $98 million agreement to settle allegations it created a subsidiary to retroactively add diagnosis codes, coupled with a five-year oversight agreement.
-
Martin’s Point Health Care’s $22.5 million settlement for inaccurate diagnosis coding claims.
These settlements often arise from whistleblower or qui tam lawsuits, brought by insiders or competitors with knowledge of alleged fraud practices. The DOJ typically joins such cases in a minority of instances but has been actively involved in several Medicare Advantage-related suits, including those against UnitedHealth.
Challenges and Prospects for UnitedHealth
UnitedHealth faces unique challenges given its size and the scope of the DOJ’s multi-faceted investigation. The company had previously confronted legal battles, such as a 2011 whistleblower suit brought by a former finance director alleging inflated risk-adjustment payments. However, this case faced a significant setback in March when a court-appointed special master recommended it be dismissed due to insufficient evidence supporting key claims.
Details about the current investigations remain limited, with the DOJ maintaining confidentiality. UnitedHealth initially denied the existence of a criminal probe but later acknowledged cooperation with federal authorities.
Lawyers and analysts caution that any resulting litigation could be lengthy and costly. J.P. Morgan analyst Lisa Gill noted that the outcome would likely depend on existing related cases and legal rulings. Moreover, given the substantial revenues generated from Medicare Advantage, some industry observers suggest that settlements might be viewed by companies as a “cost of doing business,” although Congress is increasingly signaling bipartisan interest in reforming Medicare Advantage oversight to curb fraud.
Looking Forward
The UnitedHealth investigation highlights broader concerns about the integrity of the Medicare Advantage program and raises questions about the adequacy of current regulatory frameworks. While the legal processes unfold, healthcare policymakers and advocates emphasize the need for stronger safeguards to ensure that taxpayer funds are used appropriately and that beneficiaries receive care based on accurate health information.
As this major probe progresses, stakeholders—from insurers to lawmakers—will be closely watching its development, knowing that its implications could reshape the Medicare Advantage landscape for years to come.
— Article by Mike Hughlett and Christopher Snowbeck for Smart Money Mindset